BRPI0507085A - derivados de sulfonamida, composição farmacêutica, usos, processos para preparação e combinação - Google Patents

derivados de sulfonamida, composição farmacêutica, usos, processos para preparação e combinação

Info

Publication number
BRPI0507085A
BRPI0507085A BRPI0507085-6A BRPI0507085A BRPI0507085A BR PI0507085 A BRPI0507085 A BR PI0507085A BR PI0507085 A BRPI0507085 A BR PI0507085A BR PI0507085 A BRPI0507085 A BR PI0507085A
Authority
BR
Brazil
Prior art keywords
preparation
processes
combination
pharmaceutical composition
sulfonamide derivatives
Prior art date
Application number
BRPI0507085-6A
Other languages
English (en)
Inventor
Alan Daniel Brown
Mark Edward Bunnage
Paul Alan Glossop
Kim James
Charlotte Alice Louise Lane
Russell Andrew Lewthwaite
Ian Brian Moses
David Anthony Price
Nicholas Murray Thomson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36954179&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0507085(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0406387A external-priority patent/GB0406387D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0507085A publication Critical patent/BRPI0507085A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Abstract

DERIVADOS DE SULFONAMIDA, COMPOSIçãO FARMACêUTICA, USOS, PROCESSOS PARA PREPARAçãO E COMBINAçãO. A presente invenção refere-se aos compostos da fórmula (1) e aos processos para a preparação, intermediários usados na preparação, composições contendo e aos usos de tais derivados. Os compostos de acordo com a presente invenção são úteis em numerosas doenças, distúrbios e condições, em particular doenças, distúrbios e condições inflamatórias, alérgicas e das vias respiratórias.
BRPI0507085-6A 2004-01-22 2005-01-12 derivados de sulfonamida, composição farmacêutica, usos, processos para preparação e combinação BRPI0507085A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP04290169 2004-01-22
GB0406387A GB0406387D0 (en) 2004-03-22 2004-03-22 Sulfonamide derivatives for the treatment of diseases
US60026004P 2004-08-09 2004-08-09
PCT/IB2005/000086 WO2005080313A2 (en) 2004-01-22 2005-01-12 Sulfonamide derivatives for the treatment of diseases

Publications (1)

Publication Number Publication Date
BRPI0507085A true BRPI0507085A (pt) 2007-06-19

Family

ID=36954179

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507085-6A BRPI0507085A (pt) 2004-01-22 2005-01-12 derivados de sulfonamida, composição farmacêutica, usos, processos para preparação e combinação

Country Status (30)

Country Link
US (4) US7244766B2 (pt)
EP (1) EP1708991B1 (pt)
JP (1) JP4020954B2 (pt)
AP (1) AP2359A (pt)
AR (1) AR047509A1 (pt)
AT (1) ATE375977T1 (pt)
AU (1) AU2005214153B2 (pt)
BR (1) BRPI0507085A (pt)
CA (1) CA2553789C (pt)
DE (1) DE602005002930T2 (pt)
DK (1) DK1708991T3 (pt)
DO (1) DOP2005000006A (pt)
EA (1) EA011167B1 (pt)
ES (1) ES2293530T3 (pt)
GE (1) GEP20094781B (pt)
MY (1) MY143390A (pt)
NL (1) NL1028087C2 (pt)
NO (1) NO20062983L (pt)
NZ (1) NZ548318A (pt)
OA (1) OA13362A (pt)
PA (1) PA8622001A1 (pt)
PE (1) PE20051136A1 (pt)
PL (1) PL1708991T3 (pt)
PT (1) PT1708991E (pt)
RS (1) RS50561B (pt)
SI (1) SI1708991T1 (pt)
TW (1) TWI341831B (pt)
UA (1) UA84048C2 (pt)
UY (1) UY28721A1 (pt)
WO (1) WO2005080313A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2553789C (en) * 2004-01-22 2011-07-19 Pfizer Inc. Sulfonamide derivatives for the treatment of diseases
GB0425054D0 (en) * 2004-03-23 2004-12-15 Pfizer Ltd Formamide derivatives for the treatment of diseases
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
EP1695973A1 (en) * 2005-02-24 2006-08-30 Neuro3D Ocaperidone salt and pharmaceutical compositions containing the same
US20080193988A1 (en) * 2005-07-18 2008-08-14 Iain Robert Gladwell Process for the Preparation of Sulfonamide Derivatives
RU2442771C2 (ru) 2005-08-08 2012-02-20 Арджента Дискавери Лтд Производные бицикло[2,2,1]гепт-7-иламина и их применения
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
KR20080110925A (ko) 2006-04-21 2008-12-19 노파르티스 아게 아데노신 ａ２ａ 수용체 효능제로서 사용하기 위한 퓨린 유도체
JP4948913B2 (ja) * 2006-06-16 2012-06-06 上野製薬株式会社 ナフタレンカルボン酸アミドの製造方法
PT2231642E (pt) 2008-01-11 2014-03-12 Novartis Ag Pirimidinas como inibidores de quinase
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
BRPI0923862A2 (pt) 2008-12-30 2015-07-28 Pulmagen Therapeutics Inflammation Ltd Compostos sulfonamida para o tratamento de distúrbios respiratórios
EP2435462A1 (en) 2009-05-29 2012-04-04 Pfizer Limited Novel glucocorticoid receptor agonists
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
KR20140014184A (ko) 2011-02-25 2014-02-05 아이알엠 엘엘씨 Trk 억제제로서의 화합물 및 조성물
WO2013021309A1 (en) 2011-08-11 2013-02-14 Pfizer Limited Intermediate and process for the preparation of a sulfonamide derivative
WO2021260441A1 (en) 2020-06-26 2021-12-30 Mylan Pharma Uk Limited Formulations including 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US229058A (en) * 1880-06-22 spencer
US143034A (en) * 1873-09-23 Improvement in rocking-grates
US4404224A (en) 1981-12-02 1983-09-13 American Cyanamid Company Alkanesulfonanilide derivatives and pharmaceutically acceptable acid addition salts thereof for increasing the growth rate and/or improving the lean meat to fat ratio of warm blooded animals
US4540581A (en) * 1984-01-31 1985-09-10 Bristol-Myers Company Topical nonsteroidal anti-inflammatory compositions and uses
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5264067A (en) 1992-04-23 1993-11-23 Geber Garment Technology, Inc. Adjustable length carriage compatible for use with differing spreading table widths and types
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
JPH10218861A (ja) 1997-02-04 1998-08-18 Yamanouchi Pharmaceut Co Ltd 新規なフェネタノール誘導体又はその塩
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
BR9810456A (pt) * 1997-06-27 2001-09-25 Fujisawa Pharmaceutical Co Composto de sulfonamida, método para sua obtenção e seu uso farmacêutico
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US20020143034A1 (en) * 1998-12-30 2002-10-03 Fujisawa Pharmaceutical Co. Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
HRP20000765A2 (en) * 2000-11-10 2002-06-30 Pliva D D Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release
US7048994B2 (en) 2001-02-23 2006-05-23 Teijin Limited Laminated polyester film and magnetic recording medium
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
GB2386906B (en) * 2002-03-26 2004-09-22 Japan Steel Works Ltd Heat-resisting steel and method of manufacturing the same
US6747043B2 (en) * 2002-05-28 2004-06-08 Theravance, Inc. Alkoxy aryl β2 adrenergic receptor agonists
EP1477167A1 (en) * 2003-05-15 2004-11-17 Pfizer Limited [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists
CA2553789C (en) * 2004-01-22 2011-07-19 Pfizer Inc. Sulfonamide derivatives for the treatment of diseases

Also Published As

Publication number Publication date
US20050182091A1 (en) 2005-08-18
GEP20094781B (en) 2009-09-25
JP2007518789A (ja) 2007-07-12
PT1708991E (pt) 2007-12-14
US20100273758A1 (en) 2010-10-28
DK1708991T3 (da) 2008-01-14
TW200530165A (en) 2005-09-16
EA011167B1 (ru) 2009-02-27
ES2293530T3 (es) 2008-03-16
US7767715B2 (en) 2010-08-03
ATE375977T1 (de) 2007-11-15
PL1708991T3 (pl) 2008-02-29
CA2553789C (en) 2011-07-19
SI1708991T1 (sl) 2008-02-29
DE602005002930D1 (de) 2007-11-29
US8013019B2 (en) 2011-09-06
NL1028087C2 (nl) 2006-05-09
MY143390A (en) 2011-05-13
AU2005214153A1 (en) 2005-09-01
EA200601223A1 (ru) 2006-12-29
JP4020954B2 (ja) 2007-12-12
US20090197912A1 (en) 2009-08-06
US7528170B2 (en) 2009-05-05
AR047509A1 (es) 2006-01-25
PE20051136A1 (es) 2006-02-18
CA2553789A1 (en) 2005-09-01
UY28721A1 (es) 2005-08-31
NO20062983L (no) 2006-07-24
DE602005002930T2 (de) 2008-07-24
WO2005080313A2 (en) 2005-09-01
NZ548318A (en) 2009-03-31
US7244766B2 (en) 2007-07-17
NL1028087A1 (nl) 2005-07-25
PA8622001A1 (es) 2005-08-30
AP2359A (en) 2012-01-30
US20080267970A1 (en) 2008-10-30
AU2005214153B2 (en) 2008-09-18
AP2006003669A0 (en) 2006-06-30
TWI341831B (en) 2011-05-11
WO2005080313A3 (en) 2005-12-01
UA84048C2 (ru) 2008-09-10
EP1708991A2 (en) 2006-10-11
DOP2005000006A (es) 2005-07-31
RS50561B (sr) 2010-05-07
WO2005080313A9 (en) 2006-08-31
OA13362A (en) 2007-04-13
EP1708991B1 (en) 2007-10-17

Similar Documents

Publication Publication Date Title
BRPI0507085A (pt) derivados de sulfonamida, composição farmacêutica, usos, processos para preparação e combinação
BRPI0507877A (pt) derivados de formamida, composição farmacêutica, uso dos mesmos e combinação
BRPI0410660A (pt) derivados de 2-amino-piridina como agonistas de adrenoreceptor ß2
BRPI0507041A (pt) composto derivados de sulfonamida para o tratamento de doenças seus usos, processo para a preparação dos compostos e combinação de compostos
UY28339A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
BRPI0408369A (pt) derivados de indol úteis para o tratamento de doenças
BRPI0508724A (pt) derivados do fenilaminoetanol como agonistas do receptor beta2
CR10700A (es) Derivados de sulfonamida
ECSP056164A (es) Compuestos utiles para el tratamiento de enfermedades
BRPI0510664A (pt) derivados de fenol e tiofenol 3 ou 4-monosubstituìdo úteis como ligantes de h3
AR059963A1 (es) Derivados de amina
CR8636A (es) Compuestos utiles para el tratamiento de enfermedades
BRPI0508927A (pt) compostos úteis para o tratamento de doenças
BRPI0509137A (pt) compostos para o tratamento de doenças
UY28819A1 (es) Derivados de formamida para el tratamiento de enfermedades
CR8513A (es) Derivados de sulfonamida para el tratamiento de enfermedades
DOP2004000921A (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
CU23532B7 (es) Derivados de sulfonamida para el tratamiento de enfermedades
CU23537B7 (es) Derivados de sulfonamida para el tratamiento de enfermedades
CR9838A (es) Derivados de sulfonamida para el tratamiento de enfermedades
UY28816A1 (es) Compuestos para el tratamiento de enfermedades
DOP2004000902A (es) Compuestos utiles para el tratamiento de enfermedades
DOP2005000037A (es) Compuestos utiles para el tratamiento de enfermedades
DOP2005000043A (es) Compuestos para el tratamiento de enfermedades
UY28810A1 (es) Compuestos utiles para el tratamiento de enfermedades

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.